Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
₹29 Cr
P/E Ratio
--
P/B Ratio
2.72
Industry P/E
33.87
Debt to Equity
1.31
ROE
-5.94 %
ROCE
-2.1 %
Div. Yield
0 %
Book Value
1.42
EPS
-0.03
CFO
₹7.91 Cr
EBITDA
₹-11.14 Cr
Net Profit
₹-114.23 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Transgene Biotek
| -43.48 | 1.31 | -18.57 | -51.45 | -0.85 | 1.82 | 2.75 |
|
BSE Healthcare
| -7.68 | 6.11 | -2.04 | 19.11 | 18.77 | 22.70 | 8.84 |
|
BSE Small Cap
| -12.49 | 9.35 | -8.34 | 5.55 | 17.55 | 35.38 | 15.06 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Transgene Biotek
| -29.44 | 234.58 | -33.71 | -7.04 | 113.10 | -31.29 | 40.08 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 795.30 | 9,525.83 | 71.96 | 8.24 | |
| 248.16 | 235.70 | -- | -2.98 | |
| 524.65 | 629.74 | 35.4 | 19.28 | |
| 395.30 | 2,100.05 | 70.28 | 4.87 |
No Review & Analysis are available.
Transgene Biotek Limited engages in the provision of research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics. The company offers TrabiDHA for use in health foods, baby food/formulas,... health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India. Read more
Incorporated
1990
Chairman
K Koteswara Rao
Managing Director
K Koteswara Rao
Headquarters
Bollaram, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The total asset value of Transgene Biotek Ltd stood at ₹ 142 Cr as on 31-Dec-24
The share price of Transgene Biotek Ltd is ₹3.86 (BSE) as of 17-Apr-2025 IST. Transgene Biotek Ltd has given a return of -0.85% in the last 3 years.
Transgene Biotek Ltd has a market capitalisation of ₹ 29 Cr as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Transgene Biotek Ltd is 2.72 times as on 17-Apr-2025, a 3% premium to its peers’ median range of 2.65 times.
Since, TTM earnings of Transgene Biotek Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Transgene Biotek Ltd and enter the required number of quantities and click on buy to purchase the shares of Transgene Biotek Ltd.
Transgene Biotek Limited engages in the provision of research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics. The company offers TrabiDHA for use in health foods, baby food/formulas, health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
The promoters of Transgene Biotek Ltd are DR K KOTESWARA RAO and KOLLIPARA NIRMALA. They collectively own 23.61 per cent of the total equity. The chairman of the company is K Koteswara Rao
There is no promoter pledging in Transgene Biotek Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
1,872
|
|
|
9,457
|
|
|
612
|
|
|
214
|
| Transgene Biotek Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-2.17
|
|
Operating margin(%)
|
-411.35
|
|
Net Margin(%)
|
-22.94
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Transgene Biotek Ltd was ₹0 Cr.
₹0.07
(
